FDA blocks ITM-11 radiopharma, halting challenge to Novartis therapy
The FDA has refused approval for ITM-11, a radiopharmaceutical aimed at treating rare gastroenteropancreatic neuroendocrine tumors, citing manufacturing problems.
The U.S. Food and Drug Administration has turned down ITM-11, a radiopharmaceutical developed by ITM Isotope Technologies Munich SE, because of problems with how the drug is manufactured. The agent was intended to target gastroenteropancreatic neuroendocrine tumors, a rare form of cancer affecting the pancreas, stomach, small intestine and other gastrointestinal sites. In a March 2025 report, ITM disclosed that patients receiving the infusion enjoyed a median of 23.9 months without tumor progression, outpacing the 14.1 months observed for everolimus users.
The FDA's decision stops the therapy from entering the market and removes a prospective competitor to Novartis' established product. The setback underscores the regulatory hurdles faced by emerging radiopharmaceuticals and delays a potential new treatment avenue for patients with this uncommon disease.
Why it matters
The denial delays a promising new option for a rare cancer and keeps Novartis' drug as the main treatment.
In this story